Sio Gene Therapies Inc. Common Stock
SIOX
SIOX was delisted on the 22nd of March, 2023.
95 hedge funds and large institutions have $1.43B invested in Sio Gene Therapies Inc. Common Stock in 2016 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 28 increasing their positions, 23 reducing their positions, and 12 closing their positions.
364% more call options, than puts
Call options by funds: $14.4M | Put options by funds: $3.1M
343% more capital invested
Capital invested by funds: $323M → $1.43B (+$1.11B)
117% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 12
22% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 23
17% more funds holding
Funds holding: 81 → 95 (+14)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
QF
QVT Financial
New York
|
+$1.13B |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$15.6M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$9.68M |
| 4 |
Millennium Management
New York
|
+$9.43M |
| 5 |
DM
Deerfield Management
New York
|
+$8.52M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$8.59M |
| 2 |
PA
Perceptive Advisors
New York
|
-$6.23M |
| 3 |
JP Morgan Chase
New York
|
-$5.91M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$4.25M |
| 5 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
-$3.47M |
SIOX Hedge Fund Activity: Q3 2016 in Review
95 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Sio Gene Therapies Inc. Common Stock (SIOX) for Q3 2016, worth a combined $1.43B — up 343% from $323M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new SIOX positions and 12 closed out — a net gain of 14 holders — while 28 added to existing stakes and 23 trimmed.
The largest buyer was QVT Financial, opening a new position worth an estimated $1.13B. The largest seller was Citadel Advisors, exiting entirely with an estimated $8.59M sold.
- 95 institutional investors held Sio Gene Therapies Inc. Common Stock (SIOX) as of Q3 2016, up from 81 in Q2 2016.
- Funds reported $1.43B of Sio Gene Therapies Inc. Common Stock stock for Q3 2016, up 343% quarter-over-quarter.
- 26 funds opened new Sio Gene Therapies Inc. Common Stock positions in Q3 2016 and 12 closed out, a net change of +14 holders.
- The largest Sio Gene Therapies Inc. Common Stock buyer in Q3 2016 was QVT Financial, an estimated $1.13B added.
- The largest Sio Gene Therapies Inc. Common Stock seller in Q3 2016 was Citadel Advisors, an estimated $8.59M sold.
Based on aggregated 13F filings for Q3 2016.